Trump plans to fire FDA Commissioner Makary
Analysis based on 10 articles · First reported May 08, 2026 · Last updated May 09, 2026
The planned firing of Marty Makary>>> from the United States — Food and Drug Administration>>> is expected to bring stability and predictability to the BioPharma industry, as evidenced by the 16% rise in Replimune Group>>> shares. This leadership change could lead to a more favorable regulatory environment for pharmaceutical and biotechnology companies.
President Donald Trump>>> has signed off on a plan to fire Marty Makary>>>, the Commissioner of the United States — Food and Drug Administration>>>. This decision follows a series of controversies and criticisms against Marty Makary>>> from various groups, including Donald Trump>>>'s allies, supporters of Health Secretary Robert F. Kennedy Jr.>>>, conservative media like the The Wall Street Journal>>>, pharmaceutical companies, and anti-abortion groups such as Susan B. Anthony Pro-Life America>>>. Key issues include the United States — Food and Drug Administration>>>'s rejection of Replimune Group>>>'s melanoma therapy, Marty Makary>>>'s handling of the abortion pill, and his slow approval of flavored e-cigarettes. The United States — Food and Drug Administration>>> has also experienced high-profile departures and low morale under Marty Makary>>>'s leadership. Potential replacements being considered include Kyle Diamantas>>> as acting commissioner, and Stephen Hahn>>> and Brett Giroir>>> as nominees.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard